BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32656719)

  • 21. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
    Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
    Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Outcomes after Elective
    Manguso N; Gangi A; Nissen N; Harit A; Siegel E; Hendifar A; Amersi F
    Am Surg; 2018 Oct; 84(10):1570-1574. PubMed ID: 30747671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 24. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
    Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
    Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
    Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
    Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
    Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Distal Predilection of Small Bowel Neuroendocrine Tumors.
    Keck KJ; Maxwell JE; Utria AF; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2018 Oct; 25(11):3207-3213. PubMed ID: 30054825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis.
    Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
    Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
    Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
    Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
    Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
    Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
    Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor.
    Tateishi K; Kitayama N; Matsuoka Y; Funakoshi A
    Life Sci; 1995; 57(9):889-95. PubMed ID: 7630318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
    Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.